Immune check-point in cervical cancer

F. De Felice; Claudia Marchetti; I. Palaia; R. Ostuni; L. Muzii; V. Tombolini; P. Benedetti Panici

doi:10.1016/j.critrevonc.2018.06.006

Immune check-point in cervical cancer

F. De Felice
, Claudia Marchetti
, I. Palaia
, R. Ostuni
, L. Muzii
, V. Tombolini
, P. Benedetti Panici

University of Rome La Sapienza

Research output: Contribution to journal › Article

Abstract

Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

Original language	English
Pages (from-to)	40-43
Number of pages	4
Journal	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume	129
DOIs	https://doi.org/10.1016/j.critrevonc.2018.06.006
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CTLA-4
Cervical cancer
Immune check-point
Immunotherapy
Ipilimumab
Nivolumab
PD-1
Pembrolizumab

Access to Document

10.1016/j.critrevonc.2018.06.006

Cite this

@article{9446ff3886c94d7ca426567233d982e1,

title = "Immune check-point in cervical cancer",

abstract = "Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.",

keywords = "CTLA-4, Cervical cancer, Immune check-point, Immunotherapy, Ipilimumab, Nivolumab, PD-1, Pembrolizumab, CTLA-4, Cervical cancer, Immune check-point, Immunotherapy, Ipilimumab, Nivolumab, PD-1, Pembrolizumab",

author = "\{De Felice\}, F. and Claudia Marchetti and I. Palaia and R. Ostuni and L. Muzii and V. Tombolini and \{Benedetti Panici\}, P.",

year = "2018",

doi = "10.1016/j.critrevonc.2018.06.006",

language = "English",

volume = "129",

pages = "40--43",

journal = "CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY",

issn = "1040-8428",

publisher = "-NEW YORK, USA, NY: ELSEVIER SCIENCE INC -Boca Raton, Fla.: CRC Press.",

}

TY - JOUR

T1 - Immune check-point in cervical cancer

AU - De Felice, F.

AU - Marchetti, Claudia

AU - Palaia, I.

AU - Ostuni, R.

AU - Muzii, L.

AU - Tombolini, V.

AU - Benedetti Panici, P.

PY - 2018

Y1 - 2018

N2 - Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

AB - Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

KW - CTLA-4

KW - Cervical cancer

KW - Immune check-point

KW - Immunotherapy

KW - Ipilimumab

KW - Nivolumab

KW - PD-1

KW - Pembrolizumab

KW - CTLA-4

KW - Cervical cancer

KW - Immune check-point

KW - Immunotherapy

KW - Ipilimumab

KW - Nivolumab

KW - PD-1

KW - Pembrolizumab

UR - http://hdl.handle.net/10807/203893

U2 - 10.1016/j.critrevonc.2018.06.006

DO - 10.1016/j.critrevonc.2018.06.006

M3 - Article

SN - 1040-8428

VL - 129

SP - 40

EP - 43

JO - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

JF - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

ER -

Immune check-point in cervical cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this